International Harmonization of Expedited Programs: Challenges and Opportunities for Increasing Patient Access to Innovative Therapies
Duke-Margolis Center for Health Policy Conference Center • Washington, DC
June 7, 2017

Participant List

Virginia Acha
Executive Director, Research, Medical and Innovation, The Association of the British Pharmaceutical Industry

Sandra Benton
Senior Policy Coordinator, Office of Medical Policy, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

Jacqueline J. Cinicola
Senior Director, Regulatory Affairs, Agios Pharmaceuticals, Inc.

Sarina Coates
Research Assistant, Duke-Margolis Center for Health Policy, Duke University

Jacqueline Corrigan-Curay
Director, Office of Medical Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Greg Daniel
Deputy Director, Duke-Margolis Center for Health Policy and Clinical Professor, Duke Fuqua School of Business, Duke University

Jennifer Dudinak
Vice President, Global Regulatory Affairs and Head, Pharma Regulatory Therapeutic Team, GlaxoSmithKline

Anne-Virginie Eggimann
Vice President, Regulatory Science, bluebird bio, Inc.

Daniel Feingold
Graduate Intern, Duke Margolis Center for Health Policy, Duke University

Robert Guidos
Associate Director for Legislative Affairs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Sabine Haubenreisser
European Medicines Agency Liaison Official at the FDA, European Medicines Agency

Jarno Hoekman
Assistant Professor, Innovation Studies Group, Utrecht University

Kay Holcombe
Senior Vice President for Science Policy, Biotechnology Innovation Organization

Sandra J. Horning
Chief Medical Officer and Global Head of Product Development, Genentech

Maureen M. Japha
Director, Regulatory Policy, FasterCures

Jonathan Jarow
Senior Medical Advisor, Office of the Center Director, Center For Drug Evaluation And Research, U.S. Food and Drug Administration

Christopher Joneckis
Associate Director for Review Management, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

David Joy
Director, Division of Regulatory Policy IV, Office of Regulatory Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
Emil Kakkis  
President and Chief Executive Officer, Ultragenyx Pharmaceutical

Saima Khan  
Vice President, Global Regulatory Head, Neuroscience and Pain, Pfizer, Inc.

Sandra Kweder  
Deputy Director, Europe Office, FDA Liaison to the European Medicines Agency, U.S. Food and Drug Administration

Lawrence Liberti  
Executive Director, Centre for Innovation in Regulatory Science

Diane Maloney  
Associate Director for Policy, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

Mark H. Mayer  
Senior Advisor, Global Regulatory Policy, Eli Lilly and Company

Mark McClellan  
Robert J. Margolis Professor of Business, Medicine, and Policy and Director, Duke-Margolis Center for Health Policy, Duke University

Sandra Milligan  
Senior Vice President, Global Regulatory Affairs and Clinical Safety, Merck Research Laboratories

Theresa Mullin  
Director, Office of Strategic Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Miranda Raggio  
Program Manager: CDER Breakthrough Therapy, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Elizabeth Richardson  
Managing Associate, Duke-Margolis Center for Health Policy, Duke University

Khyati N. Roberts  
Head US/Canada Regulatory Policy & Intelligence, Abbvie

Paul Seligman  
Executive Director for Regulatory and Research and Development Policy, Amgen, Inc.

Khushboo Sharma  
Team Leader, Regulatory Affairs Team, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Jay P. Siegel  
Chief Biotechnology Officer and Head, Scientific Strategy and Policy, Johnson & Johnson

Peter Stein  
Deputy Director, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Jerry R. Stewart  
Deputy Vice President, Scientific and Regulatory Advocacy, Pharmaceutical Research and Manufacturers of America

Mark Stewart  
Senior Science Policy Analyst, Friends of Cancer Research

Daniel Takefman  
Head of Regulatory Affairs, Spark Therapeutics

Tania Teixeira  
Scientific Administrator, International Affairs, European Medicines Agency

Henrietta Ukwu  
Head, Global Quality and Global Regulatory Affairs Otsuka Pharmaceuticals

Funding for this workshop was made possible in part by a cooperative agreement from the U.S. Food and Drug Administration Center for Drug Evaluation and Research. The views expressed in written workshop materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services nor does mention of trade names, commercial practices, or organizations imply endorsements by the U.S. Government.